Skip to main content
Interpace's molecular thyroid test scores reimbursement win

Cigna has agreed to cover Interpace Diagnostics' ThyGenX molecular thyroid test, a next-generation sequencing test that identifies over 100 papillary and follicular thyroid carcinoma-related genetic alterations. The coverage, which takes effect immediately, makes the test available to around 15 million Cigna plan members nationwide.

Full Story: